Biomimetic cell membrane-coated nanocarriers have gained attention as an innovative therapeutic strategy for cardiovascular diseases (CVDs) due to their capacity to mimic natural cellular architectures. This distinctive characteristic improves biocompatibility, enables evasion of immune surveillance, and promotes targeted drug delivery to specific disease sites. By harnessing cell membrane components from sources such as red blood cells, platelets, and immune cells, these nanocarriers can transport therapeutic agents directly to pathological areas, including atherosclerotic lesions, ischemic myocardial tissue, and injured vasculature. This review highlights recent progress in the development of cell membrane-coated nanocarriers for CVD treatment, focusing on their design, mechanisms of action, and preclinical therapeutic potential. Additionally, it examines key challenges to clinical application, including such as production scalability, structural stability, and regulatory challenges, while proposing strategies to overcome these limitations. The advancement of these biomimetic nanocarriers marks a promising direction in cardiovascular medicine, offering the possibility of more efficient and less invasive therapies for CVD patients.

Objective: Though the prognostic value of the model for end-stage liver disease (MELD) score in tricuspid surgery was confirmed, the unstable international normalized ratio (INR) may affect the evaluation effectiveness of the MELD score for isolated tricuspid valve replacement (ITVR). The aim of the study was to assess the prognostic value of modified MELD for ITVR.Methods and Results: A total of 152 patients who underwent ITVR were evaluated. The adverse outcome was defined as in-hospital mortality after surgery. The receiver operating characteristic (ROC) curve analysis demonstrated that a modified MELD score with albumin replacing INR (MELD-albumin) score presented well prognostic value [area under the curve (AUC) = 0.731, p = 0.006] for in-hospital mortality. Through Cox regression and further interval validation, the MELD-albumin score was identified as an independent predictor for in-hospital mortality. The optimal cutoff value of MELD-albumin was identified as 8.58 through maximally selected log-rank statistics. In addition, restricted cubic spline analysis demonstrated the linear inverse relationship between MELD-albumin and hazard ratio (HR) for in-hospital mortality. Kaplan–Meier analysis illustrated that in-hospital mortality was increased significantly in the high MELD-albumin (MELD-albumin ≥8.58) group than in the low MELD-albumin group (MELD-albumin <8.58; p < 0.001). Furthermore, high MELD-albumin was associated with lower body mass index (BMI), the incidence of lower extremities edema and moderate drinking history, and the MELD-albumin score was correlated with the value of aspartate transaminase (AST), alanine transaminase (ALT), and albumin. Furthermore, the incidence of renal failure (p = 0.003) and pulmonary infection (p = 0.042) was increased significantly in the high MELD-albumin group.Conclusion: The MELD-albumin score could provide prognostic value for ITVR. In addition, the MELD-albumin score was useful in risk stratification and patient selection for patients with tricuspid regurgitation (TR) prior to ITVR.

To analyze and summarize the experiences in surgical treatment of acute pericardial tamponade. The clinical data of 12 consecutive patients with acute peri

Dilated cardiomyopathy (DCM) is currently the most prevalent form of cardiomyopathy; it poses a severe threat to human health and is characterized by poor prognosis and high mortality. In this study, we prepared macrophage-membrane-coated and astragaloside-IV-loaded mesoporous silica nanoparticles (AS@MSN/TA/MM) and assessed their therapeutic effects in vitro and in vivo . The designed AS@MSN/TA/MM were spherical and had an average particle size of approximately 234 nm, a zeta potential of −24.5 mV, a drug loading capacity (LC) of 9.5% ± 0.04%, and an encapsulation efficiency (EE) of 98.9% ± 0.1%. The particles showed remarkable colloidal stability with phosphate-buffered saline or fetal bovine serum in vitro ; they also improved the doxorubicin hydrochloride (DOX)-induced oxidative stress of H9C2 cells and promoted cell proliferation. In the DOX-induced DCM mouse model, AS@MSN/TA/MM ameliorated cardiac dysfunction and hypertrophy, alleviated cardiomyocyte fibrosis, as well as suppressed serum levels of aldosterone, angiotensin II, and suppression of tumorigenicity 2. The present work sheds light on a promising therapeutic strategy for DCM and provides a robust platform for developing advanced astragaloside-IV-based nanotherapeutics.